Cost-Effectiveness Of Bezlotoxumab + Standard Of Care (SOC) Versus Placebo + Soc For The Prevention Of Recurrent Clostridium Difficile Infection In The United Kingdom

  • Ahir H
  • Jiang Y
  • Marcella S
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Objectives: Clostridium difficile infection (CDI) is associated with considerable morbidity, mortality and healthcare resource utilisation. This research aims to model and evaluate the cost-effectiveness of bezlotoxumab, a new antitoxin agent + standard of care (SOC) compared with placebo + SoC patients with recurrent CDI (rCDI) in the U.K. Methods: We developed a computer-based Markov health state transition model to simulate the natural history of CDI. Patients with CDI were followed from infection until death. Costs and effectiveness were evaluated using a third-party payer perspective. Recurrence rates were taken from point estimates taken from pooled data of the two phase 3 clinical trials. Transition probabilities and costs of rCDI were obtained from the literature. Cost-effectiveness analysis was conducted in three different patient populations: the entire clinical trial population, CDI patients at higher risk of rCDI-aged 65 years or above, and those with a prior history of rCDI within 6 months. Costs and benefits were discounted annually at 3.5% Results: The model predicted that treating patients with bezlotoxumab + SoC resulted in 0.1170, 0.1022, and 0.1628 incremental discounted QALYs gained per patient for the trial population, ≥ 65 years and those with a prior history, respectively. The increment discounted costs were £1,321.15, £630.38, and £670.58 in these three groups. Incremental cost-effectiveness ratios were estimated at £11,287.55, £6,170.30, and £4,117.84 per QALY gained for the trial population, ≥ 65 years and those with a prior history, respectively. Key influential parameters include CDI-specific mortality, cost of an rCDI episode, and underlying recurrence rate. ConClusions: Based on the Markov model, bezlotoxumab in combination with SoC has the potential to reduce the disease burden associated with CDI in a cost-effective manner, by reducing the incidence of rCDI.

Cite

CITATION STYLE

APA

Ahir, H., Jiang, Y., Marcella, S., & Tierney, P. (2017). Cost-Effectiveness Of Bezlotoxumab + Standard Of Care (SOC) Versus Placebo + Soc For The Prevention Of Recurrent Clostridium Difficile Infection In The United Kingdom. Value in Health, 20(9), A790. https://doi.org/10.1016/j.jval.2017.08.2319

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free